Literature DB >> 1319995

Identification of an N-terminal domain of eukaryotic DNA topoisomerase I dispensable for catalytic activity but essential for in vivo function.

J Alsner1, J Q Svejstrup, E Kjeldsen, B S Sørensen, O Westergaard.   

Abstract

We have found that deletion of a 70-amino acid domain, spanning from position 141 to 210 in the N-terminal part of human topoisomerase I, has no effect on the catalytic activity of the enzyme in vitro but suppresses the lethal consequence of overexpressing human topoisomerase I in a rad52 top1 Saccharomyces cerevisiae strain. By immunostaining, the 70-amino acid domain is shown to be necessary for nuclear location of topoisomerase I. We demonstrate that the nuclear localization signal from the SV40 large T antigen can substitute for the 70-amino acid domain, restoring both the lethal effect of overexpression and the correct subcellular localization of topoisomerase I. Thus, we have identified a domain in the N-terminal part of human topoisomerase I, nonessential for catalytic activity in vitro but serving an in vivo function by directing the enzyme to the nucleus. Based on sequence comparisons, we suggest that this domain is a conserved element in the apparently non-homologous N-terminal parts of yeast and human topoisomerase I.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1319995

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.

Authors:  Yinghui Mao; Issac R Mehl; Mark T Muller
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-22       Impact factor: 11.205

2.  Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.

Authors:  Morten O Christensen; Hans U Barthelmes; Fritz Boege; Christian Mielke
Journal:  Nucleic Acids Res       Date:  2003-12-15       Impact factor: 16.971

Review 3.  Human DNA topoisomerase I: relaxation, roles, and damage control.

Authors:  John B Leppard; James J Champoux
Journal:  Chromosoma       Date:  2005-04-14       Impact factor: 4.316

4.  Phosphorylation of serine residues in the N-terminal domains of eukaryotic type I topoisomerases.

Authors:  K Staron; D S Samuels
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

Review 5.  DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?

Authors:  A K Larsen; C Gobert
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

6.  Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Authors:  Komaraiah Palle; Luca Pattarello; Marié van der Merwe; Carmen Losasso; Piero Benedetti; Mary-Ann Bjornsti
Journal:  J Biol Chem       Date:  2008-08-08       Impact factor: 5.157

7.  Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition.

Authors:  Gary S Laco; Yves Pommier
Journal:  Biochem J       Date:  2008-05-01       Impact factor: 3.857

8.  Interaction between the N-terminal domain of human DNA topoisomerase I and the arginine-serine domain of its substrate determines phosphorylation of SF2/ASF splicing factor.

Authors:  E Labourier; F Rossi; I E Gallouzi; E Allemand; G Divita; J Tazi
Journal:  Nucleic Acids Res       Date:  1998-06-15       Impact factor: 16.971

9.  The C-terminal domain but not the tyrosine 723 of human DNA topoisomerase I active site contributes to kinase activity.

Authors:  F Rossi; E Labourier; I E Gallouzi; J Derancourt; E Allemand; G Divita; J Tazi
Journal:  Nucleic Acids Res       Date:  1998-06-15       Impact factor: 16.971

10.  Adaptation of topoisomerase I paralogs to nuclear and mitochondrial DNA.

Authors:  Ilaria Dalla Rosa; Steffi Goffart; Melanie Wurm; Constanze Wiek; Frank Essmann; Stefan Sobek; Peter Schroeder; Hongliang Zhang; Jean Krutmann; Helmut Hanenberg; Klaus Schulze-Osthoff; Christian Mielke; Yves Pommier; Fritz Boege; Morten O Christensen
Journal:  Nucleic Acids Res       Date:  2009-08-31       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.